We are investigating whether Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its executives may be liable for securities fraud.
On August 17, 2020, Applied Therapeutics disclosed that the U.S. Food and Drug Administration had placed a partial clinical hold on the Company’s ACTION-Kids study, evaluating the Company’s AT-007 product for the treatment of galactosemia. The FDA cited the need for additional technical information relating to ensuring that each study participant has access to the drug’s benefits. On this news, shares of Applied Therapeutics’ stock fell $3.53 per share, or 12.07%, to close at $25.71.
To find out how to potentially recover your losses, please complete the contact form below.